Dias E Silva D, Borad M, Uson Junior PLS. Current efficacy of hepatic arterial infusion chemotherapy in hepatocellular carcinoma. World J Gastrointest Oncol 2024; 16(12): 4766-4769 [DOI: 10.4251/wjgo.v16.i12.4766]
Corresponding Author of This Article
Pedro Luiz Serrano Uson Junior, MD, Assistant Professor, Center for Personalized Medicine, Hospital Israelita Albert Einstein, Avenida Albert Einstein 627, São Paulo 05652900, Sao Paulo, Brazil. pedro.serrano@einstein.br
Research Domain of This Article
Oncology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Dec 15, 2024; 16(12): 4766-4769 Published online Dec 15, 2024. doi: 10.4251/wjgo.v16.i12.4766
Current efficacy of hepatic arterial infusion chemotherapy in hepatocellular carcinoma
Douglas Dias E Silva, Mitesh Borad, Pedro Luiz Serrano Uson Junior
Douglas Dias E Silva, Department of Oncology, Hospital Israelita Albert Einstein, São Paulo 05652900, Sao Paulo, Brazil
Mitesh Borad, Division of Hematology-Oncology, Department of Medicine, Mayo Clinic Arizona, Mayo Clinic Cancer Center, Phoenix, AZ 85054, United States
Pedro Luiz Serrano Uson Junior, Center for Personalized Medicine, Hospital Israelita Albert Einstein, São Paulo 05652900, Sao Paulo, Brazil
Author contributions: Dias e Silva D, Borad M, and Uson Junior PLS wrote and revised the article, reviewed the literature, and approved the final version of the manuscript.
Conflict-of-interest statement: The authors declare no conflicts-of-interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Pedro Luiz Serrano Uson Junior, MD, Assistant Professor, Center for Personalized Medicine, Hospital Israelita Albert Einstein, Avenida Albert Einstein 627, São Paulo 05652900, Sao Paulo, Brazil. pedro.serrano@einstein.br
Received: July 21, 2024 Revised: August 28, 2024 Accepted: October 12, 2024 Published online: December 15, 2024 Processing time: 113 Days and 17.8 Hours
Abstract
Newer systemic therapies for hepatocellular carcinoma (HCC) have led to growing interest in combining hepatic arterial infusion chemotherapy (HAIC) with systemic treatments. To evaluate the effectiveness and safety of HAIC and combination therapies in treating advanced HCC, a network meta-analysis was conducted by Zhou et al. The study included data from 44 articles. HAIC was superior in overall survival (OS), progression-free survival (PFS), and response rates compared to transarterial chemoembolization and sorafenib. Moreover, combinations of HAIC with other treatments and single agents (e.g., lenvatinib, ablation, anti-programmed cell death 1 therapy, radiotherapy) provided better OS and PFS outcomes than HAIC alone. In this editorial, we will discuss the study findings, the strengths and weaknesses of the metanalysis, and future advances in the field of HAIC for advanced HCC.
Core Tip: This meta-analysis provides a valuable and comprehensive evaluation of hepatic arterial infusion chemotherapy (HAIC) and its combination therapies for advanced hepatocellular carcinoma. Compared to other treatments including transarterial chemoembolization, HAIC showed favorable outcomes including response rate and survival. Furthermore, based on the findings, combination of HAIC with antiangiogenics and even immune checkpoint inhibitors seems to improve efficacy when compared to HAIC alone.
